出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2024年1月
Infectious Disease Diagnostics Market – Global Forecast to 2028
感染症診断市場 : 製品とサービス (試薬、キット)、検査タイプ (ラボ、PoC)、サンプル (血液、尿)、技術 (免疫診断、NGS、PCR、ISH、INAAT)、疾患 (肝炎、HIV、HAI、HPV、梅毒、結核) 、インフルエンザ) – 2028年までの世界予測
Infectious Disease Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (Immunodiagnostics, NGS, PCR, ISH, INAAT), Disease (Hepatitis, HIV, HAI, HPV, Syphilis, TB, Flu) – Global Forecast to 2028
| ページ数 | 303 |
| 図表数 | 225 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The infectious disease diagnostics market is valued at an estimated USD 21.4 billion in 2023 and is projected to reach USD 31.5 billion by 2028 at a CAGR of 8.0% during the forecast period. The rising focus on decentralized diagnostics and the growing demand for CLIA-waived PoC tests have driven the use of PoC technologies. The trend towards decentralized PoC testing in the infectious disease diagnostics market is further fueled by the need for more efficient healthcare delivery. Centralized laboratories often face challenges such as longer turnaround times and logistical complexities, particularly in remote or underserved areas. The decentralization of testing to point-of-care settings empowers healthcare professionals with the ability to conduct diagnostics at the patient’s side, reducing the time between sample collection and result delivery. This paradigm shift not only supports timely patient care but also aids in the prompt identification and containment of infectious diseases, ultimately contributing to improved public health outcomes.
“PoC testing segment accounted for the highest growth rate in the infectious disease diagnostics market, by type of testing, during the forecast period.”
The infectious disease diagnostics market is bifurcated into laboratory testing and PoC testing. The PoC testing segment in the infectious disease diagnostics market is experiencing substantial growth. The growth of the PoC segment is being fueled by the investments made by numerous companies, including their focus on new developments such as product launches and acquisitions. One of the main advantages of using PoC testing in hospitals or clinics over laboratory tests is that they have a faster turnaround time for testing than laboratory tests. Additionally, PoC testing requires lower sample volumes than traditional laboratory tests. Thus, the need to closely monitor patient conditions and advantages such as a faster diagnosis rate are the major factors driving the demand for PoC tests.
“DNA sequencing & next-generation sequencing segment accounted for the highest growth rate in the infectious disease diagnostics market, by technology, during the forecast period.”
The infectious disease diagnostics market is bifurcated into immunodiagnostics, clinical microbiology, polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarray, and other technologies based on technology. DNA sequencing & next-generation sequencing segment is expected to account for the highest CAGR during the forecast period. DNA sequencing is an easy platform that can be set up directly in the clinic for quick results. The ability to sequence DNA has opened opportunities for applications in various research fields, such as personalized medicine, cancer research, drug discovery, and agricultural and animal sciences. Factors such as advancements in sequencing technologies, a wide range of applications of sequencing technologies, and the growing demand for personalized medicine are factors expected to support market growth in the coming years.
“Asia Pacific: The fastest-growing region infectious disease diagnostics market”
The global infectious disease diagnostics market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to witness the highest growth during the forecast period. Emerging countries in this region are witnessing growth in their GDPs and a significant rise in disposable income levels. This has led to increased healthcare spending by a larger population base. Other factors such as the increasing incidence & prevalence of infectious diseases, healthcare infrastructure modernization, and the rising penetration of cutting-edge technologies (especially in rural areas) in Asia Pacific countries are also expected to provide significant growth opportunities for infectious disease diagnostics companies in this region.
The break-up of the profile of primary participants in the infectious disease diagnostics market:
• By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and Middle East & Africa- 4%
The key players in this market are Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Siemens Healthineers AG (Germany), Danaher (US), Hologic, Inc. (US), Becton, Dickinson and Company (US), Revvity (US), QIAGEN (Netherlands), Seegene Inc. (South Korea), Grifols, S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), QuidelOrtho Corporation (US), Meridian Bioscience (US), Genetic Signatures Ltd. (Australia), OraSure Technologies (US), Trinity Biotech (Ireland), Chembio Diagnostics, Inc. (US), Co-Diagnostics, Inc. (US), ELITech Group (France), Epitope Diagnostics, Inc. (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International, Inc. (US), Vela Diagnostics (Singapore), and Uniogen Oy (Finland).
Research Coverage:
This research report categorizes the infectious disease diagnostics market by product & service (reagents, kits, and consumables, instruments, and software & services), by type of testing (laboratory testing, PoC testing), by technology (immunodiagnostics, polymerase chain reaction, clinical microbiology, isothermal nucleic acid amplification technology, dna sequencing & next-generation sequencing, dna microarray, and other technologies), by disease type (hepatitis, HIV, hospital-acquired infections, mosquito-borne diseases, HPV, Chlamydia trachomatis, Neisseria gonorrhea, tuberculosis, influenza, syphilis, and other infectious diseases), by sample type (blood, serum, and plasma, urine, and other sample types), by end user (diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the infectious disease diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches and recent developments associated with the infectious disease diagnostics market. Competitive analysis of upcoming startups in the infectious disease diagnostics market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall infectious disease diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Rising prevalence of infectious diseases, Rising focus on R&D and funding in infectious disease diagnostic products, Growing awareness for early disease diagnosis in emerging economies, Adoption of new and advanced technologies for infectious disease diagnosis, Shift in focus from centralized laboratories to decentralized PoC testing centers), opportunities (Increased growth opportunities in emerging economies), restraints (Unfavorable reimbursement scenario), and challenges (Changing regulatory landscape, Operational barriers and shortage of skilled laboratory technicians) influencing the growth of the infectious disease diagnostics market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the infectious disease diagnostics market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the infectious disease diagnostics market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the infectious disease diagnostics market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Siemens Healthineers AG (Germany), Danaher (US), and Thermo Fisher Scientific Inc. (US), among others in the infectious disease diagnostics market strategies.
Table of Contents
1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.3 INCLUSIONS & EXCLUSIONS 34
1.4 STUDY SCOPE 35
1.4.1 MARKETS COVERED 35
1.4.2 REGIONS COVERED 36
1.4.3 YEARS CONSIDERED 36
1.4.4 CURRENCY CONSIDERED 37
1.5 RESEARCH LIMITATIONS 37
1.6 STAKEHOLDERS 37
1.7 SUMMARY OF CHANGES 38
2 RESEARCH METHODOLOGY 39
2.1 RESEARCH DATA 39
2.2 RESEARCH APPROACH 39
FIGURE 1 RESEARCH DESIGN METHODOLOGY 39
2.2.1 SECONDARY DATA 40
2.2.1.1 Key data from secondary sources 41
2.2.2 PRIMARY DATA 42
FIGURE 2 PRIMARY SOURCES 42
2.2.2.1 Key data from primary sources 43
2.2.3 KEY INDUSTRY INSIGHTS 44
2.2.3.1 Breakdown of primary interviews 44
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 44
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 45
2.3 MARKET SIZE ESTIMATION 45
2.3.1 BOTTOM-UP APPROACH 46
2.3.2 COMPANY REVENUE ESTIMATION APPROACH 46
FIGURE 5 COMPANY REVENUE ESTIMATION APPROACH: INFECTIOUS DISEASE DIAGNOSTICS MARKET 46
2.3.3 PRESENTATIONS OF COMPANIES AND PRIMARY INTERVIEWS 46
2.3.4 GROWTH FORECAST 47
2.3.5 CAGR PROJECTIONS 47
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 47
2.3.6 TOP-DOWN APPROACH 47
FIGURE 7 TOP-DOWN APPROACH 48
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 49
FIGURE 8 DATA TRIANGULATION METHODOLOGY 49
2.5 MARKET SHARE ASSESSMENT 50
2.6 STUDY ASSUMPTIONS 50
2.6.1 GROWTH RATE ASSUMPTIONS 50
2.7 RISK ASSESSMENT 51
TABLE 1 RISK ASSESSMENT: INFECTIOUS DISEASE DIAGNOSTICS MARKET 51
2.8 IMPACT OF RECESSION ON INFECTIOUS DISEASE DIAGNOSTICS MARKET 51
3 EXECUTIVE SUMMARY 53
FIGURE 9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 53
FIGURE 10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023 VS. 2028 (USD MILLION) 54
FIGURE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION) 55
FIGURE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 56
FIGURE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD MILLION) 57
FIGURE 14 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 58
FIGURE 15 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 58
4 PREMIUM INSIGHTS 60
4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW 60
FIGURE 16 GROWING PREVALENCE OF INFECTIOUS DISEASE AND INCREASING INVESTMENT IN R&D TO DRIVE MARKET 60
4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 61
FIGURE 17 REAGENTS, KITS, AND CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 61
4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023 VS. 2028 (USD MILLION) 61
FIGURE 18 LABORATORY TESTING TO DOMINATE MARKET DURING STUDY PERIOD 61
4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION) 62
FIGURE 19 BLOOD, SERUM, AND PLASMA TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD 62
4.5 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 62
FIGURE 20 IMMUNODIAGNOSTICS TO DOMINATE MARKET DURING FORECAST PERIOD 62
4.6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD MILLION) 63
FIGURE 21 HEPATITIS TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD 63
4.7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 63
FIGURE 22 DIAGNOSTIC LABORATORIES TO DOMINATE MARKET DURING STUDY PERIOD 63
4.8 REGIONAL GROWTH OPPORTUNITIES 64
FIGURE 23 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 64
5 MARKET OVERVIEW 65
5.1 INTRODUCTION 65
5.2 MARKET DYNAMICS 65
FIGURE 24 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: INFECTIOUS DISEASE DIAGNOSTICS MARKET 65
5.2.1 DRIVERS 66
5.2.1.1 Rising prevalence of infectious diseases 66
5.2.1.2 Rising focus on R&D and funding for infectious disease diagnostic products 67
5.2.1.3 Growing awareness for early disease diagnosis in emerging economies 68
5.2.1.4 Adoption of new and advanced technologies for infectious disease diagnosis 68
5.2.1.5 Shift in focus from centralized laboratories to decentralized PoC testing centers 69
5.2.2 RESTRAINTS 70
5.2.2.1 Unfavorable reimbursement scenario 70
5.2.3 OPPORTUNITIES 70
5.2.3.1 Increased growth opportunities in emerging economies 70
5.2.4 CHALLENGES 71
5.2.4.1 Changing regulatory landscape 71
5.2.4.2 Operational barriers and shortage of skilled laboratory technicians 71
5.3 PRICING ANALYSIS 71
TABLE 2 INDICATIVE PRICING FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS 71
TABLE 3 AVERAGE SELLING PRICE OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION 72
5.4 PATENT ANALYSIS 73
FIGURE 25 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013–DECEMBER 2022) 73
TABLE 4 LIST OF MAJOR PATENTS, JANUARY 2021–DECEMBER 2022 74
5.5 VALUE CHAIN ANALYSIS 75
FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 75
5.6 SUPPLY CHAIN ANALYSIS 76
FIGURE 27 SUPPLY CHAIN ANALYSIS: INFECTIOUS DISEASE DIAGNOSTICS MARKET 77
5.7 ECOSYSTEM MARKET MAP 77
FIGURE 28 ECOSYSTEM MARKET MAP: INFECTIOUS DISEASE DIAGNOSTICS MARKET 78
TABLE 5 ROLE IN ECOSYSTEM 78
5.8 PORTER’S FIVE FORCES ANALYSIS 79
TABLE 6 PORTER’S FIVE FORCES ANALYSIS 79
5.8.1 THREAT OF NEW ENTRANTS 79
5.8.2 THREAT OF SUBSTITUTES 79
5.8.3 BARGAINING POWER OF BUYERS 79
5.8.4 BARGAINING POWER OF SUPPLIERS 80
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 80
5.9 REGULATORY LANDSCAPE 80
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 8 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 9 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
5.9.2 NORTH AMERICA 82
5.9.2.1 US 82
5.9.2.2 Canada 82
5.9.3 EUROPE 82
TABLE 11 EUROPE: CLASSIFICATION OF DEVICES 83
5.9.4 ASIA PACIFIC 83
5.9.4.1 China 83
5.9.4.2 Japan 83
TABLE 12 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 84
5.9.4.3 India 84
5.9.5 LATIN AMERICA 84
5.9.5.1 Brazil 84
5.9.5.2 Mexico 85
5.9.6 MIDDLE EAST 85
5.9.6.1 Africa 85
5.10 TRADE ANALYSIS 85
TABLE 13 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 85
TABLE 14 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 86
5.11 TECHNOLOGY ANALYSIS 86
5.12 KEY CONFERENCES & EVENTS 87
TABLE 15 DETAILED LIST OF KEY CONFERENCES & EVENTS IN 2O22–2023 87
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 89
FIGURE 29 REVENUE SHIFT IN INFECTIOUS DISEASE DIAGNOSTICS MARKET 89
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 90
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 90
FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS 90
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (%) 90
5.14.2 BUYING CRITERIA 91
FIGURE 31 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS 91
TABLE 17 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS 91
5.15 CASE STUDY ANALYSIS 92
FIGURE 32 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR IN INDIA 92
6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 93
6.1 INTRODUCTION 94
TABLE 18 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 94
TABLE 19 PRICES OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, 2022 94
6.2 REAGENTS, KITS, AND CONSUMABLES 95
6.2.1 RECURRENT PURCHASES OF REAGENTS, KITS, AND CONSUMABLES TO DRIVE MARKET 95
TABLE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY REGION, 2021–2028 (USD MILLION) 96
6.3 INSTRUMENTS 96
6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS WITH MINIMUM HUMAN INTERVENTION TO DRIVE MARKET 96
TABLE 21 KEY INSTRUMENTS AVAILABLE IN MARKET 97
TABLE 22 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 98
6.4 SOFTWARE & SERVICES 98
6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS AND INCREASING COMPETITIVENESS FOR VALUE-ADDED SERVICES TO DRIVE MARKET 98
TABLE 23 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2028 (USD MILLION) 99
7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING 100
7.1 INTRODUCTION 101
TABLE 24 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2021–2028 (USD MILLION) 101
7.1.1 PRIMARY NOTES 101
FIGURE 33 KEY INDUSTRY INSIGHTS: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING 101
7.2 LABORATORY TESTING 102
7.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET 102
TABLE 25 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY REGION, 2021–2028 (USD MILLION) 103
7.3 POC TESTING 103
7.3.1 FASTER TURNAROUND TIME AND MORE EFFICIENT TREATMENT OPTIONS TO DRIVE MARKET 103
TABLE 26 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY REGION, 2021–2028 (USD MILLION) 104
8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE 105
8.1 INTRODUCTION 106
TABLE 27 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 106
8.1.1 PRIMARY NOTES 106
FIGURE 34 KEY INDUSTRY INSIGHTS: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE 106
8.2 BLOOD, SERUM, AND PLASMA 107
8.2.1 HIGHER VERSATILITY, GREATER CLINICAL EFFICACY, AND BETTER REIMBURSEMENT POLICIES TO DRIVE MARKET 107
TABLE 28 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021–2028 (USD MILLION) 108
8.3 URINE 108
8.3.1 NON-INVASIVE NATURE OF URINE SAMPLES TO DRIVE MARKET 108
TABLE 29 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION) 109
8.4 OTHER SAMPLE TYPES 109
TABLE 30 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021–2028 (USD MILLION) 109
9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE 110
9.1 INTRODUCTION 111
TABLE 31 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 111
9.2 HEPATITIS 111
TABLE 32 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2021–2028 (USD MILLION) 112
TABLE 33 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2021–2028 (MILLION TESTS) 113
TABLE 34 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY METHOD, 2021–2028 (USD MILLION) 113
TABLE 35 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2021–2028 (USD MILLION) 113
9.2.1 HEPATITIS B 114
9.2.1.1 Increasing global prevalence of hepatitis B to drive segment 114
TABLE 36 HEPATITIS B MARKET, BY REGION, 2021–2028 (USD MILLION) 114
9.2.2 HEPATITIS C 114
9.2.2.1 Rising number of government initiatives for hepatitis C diagnosis to drive segment 114
TABLE 37 HEPATITIS C MARKET, BY REGION, 2021–2028 (USD MILLION) 115
9.2.3 OTHER HEPATITIS DISEASES 115
TABLE 38 OTHER HEPATITIS DISEASES MARKET, BY REGION, 2021–2028 (USD MILLION) 116
9.3 HIV 116
9.3.1 GROWING PREVALENCE OF AIDS AND INCREASING AVAILABILITY OF HIV POC TESTING TO DRIVE MARKET 116
TABLE 39 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2021–2028 (USD MILLION) 117
TABLE 40 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2021–2028 (MILLION TESTS) 117
9.4 HOSPITAL-ACQUIRED INFECTIONS 117
9.4.1 RISING BURDEN OF INFECTIONS AND INCREASING ADOPTION OF ADVANCED DIAGNOSTIC TESTS TO DRIVE MARKET 117
TABLE 41 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 42 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021–2028 (MILLION TESTS) 119
9.5 MOSQUITO-BORNE DISEASES 119
9.5.1 RISING INCIDENCE OF DENGUE AND MALARIA AND INCREASING NUMBER OF AWARENESS PROGRAMS TO DRIVE MARKET 119
TABLE 43 MAJOR PRODUCTS FOR DENGUE TESTING AVAILABLE IN MARKET 120
TABLE 44 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY REGION, 2021–2028 (USD MILLION) 121
9.6 HPV 121
9.6.1 TECHNOLOGICAL ADVANCEMENTS FOR PREVENTING HPV INFECTIONS TO DRIVE MARKET 121
TABLE 45 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2021–2028 (USD MILLION) 122
TABLE 46 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2021–2028 (MILLION TESTS) 122
9.7 CHLAMYDIA TRACHOMATIS 122
9.7.1 GROWING INCIDENCE OF CHLAMYDIA AND RISING AWARENESS AMONG PATIENTS TO DRIVE MARKET 122
TABLE 47 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2021–2028 (USD MILLION) 123
TABLE 48 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2021–2028 (MILLION TESTS) 123
9.8 NEISSERIA GONORRHEA 124
9.8.1 RISING INCIDENCE OF GONORRHEA AND GROWING FUNDING FOR R&D TO DRIVE MARKET 124
TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA, BY REGION, 2021–2028 (USD MILLION) 124
9.9 TUBERCULOSIS 124
9.9.1 INCREASING BURDEN OF TUBERCULOSIS IN UNDERDEVELOPED NATIONS TO DRIVE MARKET 124
TABLE 50 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2021–2028 (USD MILLION) 125
TABLE 51 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2021–2028 (MILLION TESTS) 125
TABLE 52 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY METHOD, 2021–2028 (USD MILLION) 126
9.10 INFLUENZA 126
9.10.1 RISING FOCUS ON FASTER DIAGNOSIS AND CONTROL TO DRIVE MARKET 126
TABLE 53 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 54 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2021–2028 (MILLION TESTS) 127
TABLE 55 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY METHOD, 2021–2028 (USD MILLION) 127
9.11 SYPHILIS 127
9.11.1 GROWING ADOPTION OF NOVEL TECHNOLOGIES FOR IMPROVED SCREENING TO DRIVE MARKET 127
TABLE 56 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION, 2021–2028 (USD MILLION) 128
9.12 OTHER INFECTIOUS DISEASES 128
TABLE 57 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 129
9.13 COVID-19 129
9.13.1 DECLINING CASES OF COVID-19 TO LIMIT MARKET 129
TABLE 58 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2021–2028 (USD MILLION) 130
10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY 131
10.1 INTRODUCTION 132
10.2 PRIMARY NOTES 132
FIGURE 35 KEY INDUSTRY INSIGHTS: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY 132
TABLE 59 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 133
10.3 IMMUNODIAGNOSTICS 133
10.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET 133
TABLE 60 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 134
10.4 CLINICAL MICROBIOLOGY 134
10.4.1 QUICKER TURNAROUND TIME FOR RESULTS WITH HIGHER SENSITIVITY AND RELIABILITY TO DRIVE MARKET 134
TABLE 61 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2021–2028 (USD MILLION) 135
10.5 POLYMERASE CHAIN REACTION 135
10.5.1 EASE OF USE, COST-EFFECTIVENESS, AND HIGH SPECIFICITY TO DRIVE MARKET 135
TABLE 62 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021–2028 (USD MILLION) 136
10.6 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY 137
10.6.1 LOWER COST AND BETTER SUITABILITY FOR POINT-OF-CARE TESTING TO DRIVE MARKET 137
TABLE 63 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION) 137
10.7 DNA SEQUENCING & NEXT-GENERATION SEQUENCING 138
10.7.1 ADVANCEMENTS IN SEQUENCING TECHNOLOGIES AND INCREASED FOCUS ON MOLECULAR TARGETED DRUGS TO DRIVE MARKET 138
TABLE 64 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2021–2028 (USD MILLION) 138
10.8 DNA MICROARRAY 139
10.8.1 HIGH INSTRUMENT COSTS AND NEED FOR EXPERT TECHNICIANS TO LIMIT MARKET 139
TABLE 65 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAY, BY REGION, 2021–2028 (USD MILLION) 139
10.9 OTHER TECHNOLOGIES 139
TABLE 66 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION) 140
11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER 141
11.1 INTRODUCTION 142
TABLE 67 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 142
11.2 DIAGNOSTIC LABORATORIES 142
11.2.1 DEVELOPMENT OF LOW-COST AND HIGHLY SPECIALIZED SCREENING TESTS TO DRIVE MARKET 142
TABLE 68 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 143
11.3 HOSPITALS & CLINICS 143
11.3.1 INCREASING ADOPTION OF DIAGNOSTIC TOOLS AND BETTER REIMBURSEMENT FACILITIES TO DRIVE MARKET 143
TABLE 69 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021–2028 (USD MILLION) 144
11.4 ACADEMIC RESEARCH INSTITUTES 144
11.4.1 INCREASING FOCUS ON R&D FOR DEVELOPING INNOVATIVE TESTS TO DRIVE MARKET 144
TABLE 70 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 145
11.5 OTHER END USERS 145
TABLE 71 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 146
12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION 147
12.1 INTRODUCTION 148
TABLE 72 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION,
2021–2028 (USD MILLION) 148
12.2 NORTH AMERICA 148
FIGURE 36 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT 149
TABLE 73 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 74 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 150
TABLE 75 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 150
TABLE 76 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 151
TABLE 77 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 151
12.2.1 NORTH AMERICA: RECESSION IMPACT 152
12.2.2 US 152
12.2.2.1 Increasing prevalence of infectious diseases to drive market 152
TABLE 78 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 152
TABLE 79 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 153
TABLE 80 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 153
TABLE 81 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 154
12.2.3 CANADA 154
12.2.3.1 Focus on affordable tests and use of personalized medicine to drive market 154
TABLE 82 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 154
TABLE 83 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 155
TABLE 84 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 155
TABLE 85 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 156
12.3 EUROPE 156
TABLE 86 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 87 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 157
TABLE 88 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 158
TABLE 89 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 158
TABLE 90 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 159
12.3.1 EUROPE: RECESSION IMPACT 159
12.3.2 GERMANY 159
12.3.2.1 Increasing healthcare expenditure and rising per capita disposable income to drive market 159
TABLE 91 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 160
TABLE 92 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 160
TABLE 93 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 161
TABLE 94 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 161
12.3.3 UK 162
12.3.3.1 Growing number of accredited diagnostic and hospital laboratories to drive market 162
TABLE 95 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 162
TABLE 96 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 163
TABLE 97 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 163
TABLE 98 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 164
12.3.4 FRANCE 164
12.3.4.1 Rising R&D expenditure and increasing demand for early diagnosis to drive market 164
TABLE 99 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 164
TABLE 100 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 165
TABLE 101 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 165
TABLE 102 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 166
12.3.5 ITALY 166
12.3.5.1 Increased adoption of advanced diagnostic technologies and growing government healthcare investment to drive market 166
TABLE 103 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 166
TABLE 104 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 167
TABLE 105 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 167
TABLE 106 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 168
12.3.6 SPAIN 168
12.3.6.1 Rising geriatric population and improving healthcare infrastructure to drive market 168
TABLE 107 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 169
TABLE 108 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 169
TABLE 109 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 170
TABLE 110 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 170
12.3.7 REST OF EUROPE 171
TABLE 111 GDP EXPENDITURE ON HEALTHCARE, BY COUNTRY (%) 171
TABLE 112 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 171
TABLE 113 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 172
TABLE 114 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 172
TABLE 115 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 173
12.4 ASIA PACIFIC 173
FIGURE 37 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT 174
TABLE 116 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 174
TABLE 117 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 175
TABLE 118 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 175
TABLE 119 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 176
TABLE 120 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 176
12.4.1 ASIA PACIFIC: RECESSION IMPACT 177
12.4.2 CHINA 177
12.4.2.1 Increased public access to modern healthcare and favorable government policies to drive market 177
TABLE 121 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 177
TABLE 122 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 178
TABLE 123 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 178
TABLE 124 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 179
12.4.3 JAPAN 179
12.4.3.1 Presence of well-developed healthcare system and universal reimbursement policies to drive market 179
TABLE 125 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 180
TABLE 126 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 180
TABLE 127 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 181
TABLE 128 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 181
12.4.4 INDIA 182
12.4.4.1 Increasing private and public investments in healthcare system to drive market 182
TABLE 129 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 182
TABLE 130 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 183
TABLE 131 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 183
TABLE 132 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 184
12.4.5 REST OF ASIA PACIFIC 184
TABLE 133 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 184
TABLE 134 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 185
TABLE 135 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 185
TABLE 136 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 186
12.5 LATIN AMERICA 186
12.5.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND INCREASING HEALTHCARE EXPENDITURE TO DRIVE MARKET 186
TABLE 137 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 187
TABLE 138 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 187
TABLE 139 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 188
TABLE 140 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 188
12.5.2 LATIN AMERICA: RECESSION IMPACT 189
12.6 MIDDLE EAST & AFRICA 189
TABLE 141 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 189
TABLE 142 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 190
TABLE 143 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 190
TABLE 144 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 191
TABLE 145 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 191
12.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT 192
12.6.2 GCC COUNTRIES 192
12.6.2.1 Rising focus on advanced health infrastructure to drive market 192
TABLE 146 GCC COUNTRIES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 193
TABLE 147 GCC COUNTRIES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 193
TABLE 148 GCC COUNTRIES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 194
TABLE 149 GCC COUNTRIES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 194
12.6.3 REST OF MIDDLE EAST & AFRICA 195
TABLE 150 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 195
TABLE 151 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 195
TABLE 152 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 196
TABLE 153 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 196
13 COMPETITIVE LANDSCAPE 197
13.1 OVERVIEW 197
13.2 KEY STRATEGIES/RIGHT TO WIN 197
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 198
TABLE 154 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET 198
13.3 REVENUE SHARE ANALYSIS 200
FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS 200
13.4 MARKET SHARE ANALYSIS 201
FIGURE 39 INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022) 201
TABLE 155 DEGREE OF COMPETITION: INFECTIOUS DISEASE DIAGNOSTICS MARKET 201
13.5 COMPANY EVALUATION MATRIX 202
13.5.1 STARS 202
13.5.2 EMERGING LEADERS 203
13.5.3 PERVASIVE PLAYERS 203
13.5.4 PARTICIPANTS 203
FIGURE 40 COMPANY EVALUATION MATRIX, 2022 203
13.5.5 COMPANY FOOTPRINT 204
FIGURE 41 PRODUCT AND REGIONAL FOOTPRINT OF KEY PLAYERS 204
TABLE 156 COMPANY FOOTPRINT 204
TABLE 157 PRODUCT & SERVICE FOOTPRINT 205
TABLE 158 REGIONAL FOOTPRINT 205
13.6 START-UP/SME EVALUATION MATRIX 206
13.6.1 PROGRESSIVE COMPANIES 206
13.6.2 RESPONSIVE COMPANIES 206
13.6.3 DYNAMIC COMPANIES 206
13.6.4 STARTING BLOCKS 206
FIGURE 42 START-UP/SME EVALUATION MATRIX, 2022 207
13.6.5 COMPETITIVE BENCHMARKING 207
TABLE 159 DETAILED LIST OF KEY START-UPS/SMES 207
13.7 COMPETITIVE SCENARIOS AND TRENDS 208
13.7.1 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS 208
TABLE 160 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS, 2020–2023 208
13.7.2 KEY DEALS 209
TABLE 161 KEY DEALS, 2020–2023 209
14 COMPANY PROFILES 210
14.1 KEY PLAYERS 210
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1 F. HOFFMANN-LA ROCHE LTD. 210
TABLE 162 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 210
FIGURE 43 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 211
14.1.2 ABBOTT 217
TABLE 163 ABBOTT: COMPANY OVERVIEW 217
FIGURE 44 ABBOTT: COMPANY SNAPSHOT (2022) 218
14.1.3 BIOMÉRIEUX 224
TABLE 164 BIOMÉRIEUX: COMPANY OVERVIEW 224
FIGURE 45 BIOMÉRIEUX: COMPANY SNAPSHOT (2022) 225
14.1.4 SIEMENS HEALTHINEERS AG 231
TABLE 165 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 231
FIGURE 46 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 232
14.1.5 DANAHER 237
TABLE 166 DANAHER: COMPANY OVERVIEW 237
FIGURE 47 DANAHER: COMPANY SNAPSHOT (2022) 238
14.1.6 THERMO FISHER SCIENTIFIC INC. 243
TABLE 167 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 243
FIGURE 48 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 244
14.1.7 HOLOGIC, INC. 249
TABLE 168 HOLOGIC, INC.: COMPANY OVERVIEW 249
FIGURE 49 HOLOGIC, INC.: COMPANY SNAPSHOT (2022) 250
14.1.8 BECTON, DICKINSON AND COMPANY 254
TABLE 169 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 254
FIGURE 50 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 255
14.1.9 REVVITY 260
TABLE 170 REVVITY: COMPANY OVERVIEW 260
FIGURE 51 REVVITY: COMPANY SNAPSHOT (2022) 261
14.1.10 QIAGEN 266
TABLE 171 QIAGEN: COMPANY OVERVIEW 266
FIGURE 52 QIAGEN: COMPANY SNAPSHOT (2022) 267
14.1.11 SEEGENE INC. 270
TABLE 172 SEEGENE INC.: COMPANY OVERVIEW 270
FIGURE 53 SEEGENE INC.: COMPANY SNAPSHOT (2022) 271
14.2 OTHER PLAYERS 276
14.2.1 QUIDELORTHO CORPORATION 276
14.2.2 GRIFOLS, S.A. 279
14.2.3 DIASORIN S.P.A. 280
14.2.4 BIO-RAD LABORATORIES, INC. 282
14.2.5 SYSMEX CORPORATION 284
14.2.6 ORASURE TECHNOLOGIES 285
14.2.7 CO-DIAGNOSTICS, INC. 286
14.2.8 MERIDIAN BIOSCIENCE 287
14.2.9 CHEMBIO DIAGNOSTICS, INC. 289
14.2.10 TRINITY BIOTECH 290
14.2.11 GENETIC SIGNATURES LTD. 291
14.2.12 EPITOPE DIAGNOSTICS, INC. 292
14.2.13 TRIVITRON HEALTHCARE 294
14.2.14 ELITECH GROUP 295
14.2.15 MERIL LIFE SCIENCES PVT. LTD. 297
14.2.16 INBIOS INTERNATIONAL, INC. 298
14.2.17 UNIOGEN OY 299
14.2.18 VELA DIAGNOSTICS 300
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
15 APPENDIX 301
15.1 DISCUSSION GUIDE 301
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 306
15.3 CUSTOMIZATION OPTIONS 308
15.4 RELATED REPORTS 308
15.5 AUTHOR DETAILS 309